Elevated baseline serum glutamate as a pharmacometabolomic biomarker for acamprosate treatment outcome in alcohol-dependent subjects

Acamprosate has been widely used since the Food and Drug Administration approved the medication for treatment of alcohol use disorders (AUDs) in 2004. Although the detailed molecular mechanism of acamprosate remains unclear, it has been largely known that acamprosate inhibits glutamate action in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Nam, H W, Karpyak, V M, Hinton, D J, Geske, J R, Ho, A M C, Prieto, M L, Biernacka, J M, Frye, M A, Weinshilboum, R M, Choi, D-S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4564571/
https://www.ncbi.nlm.nih.gov/pubmed/26285131
http://dx.doi.org/10.1038/tp.2015.120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4564571/
https://www.ncbi.nlm.nih.gov/pubmed/26285131
http://dx.doi.org/10.1038/tp.2015.120

Ejemplares similares